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Abstract
Background: MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved
that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates
expression of TNF-α, which plays a crucial role in RA pathogenesis. The aim of this study was to determine the
treatment outcome of patients with early RA based on the expression of circulating and cellular miR-125b.
Methods: Total RNA was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) of 58 patients
with early RA before and three months after treatment initiation and of 54 age- and sex-matched healthy controls
(HC). The expression of miR-125b was measured by TaqMan quantitative PCR. The treatment responders were
defined as patients achieving remission or low disease activity (28-joint count disease activity score (DAS28) <3.2).
Receiver operating characteristic (ROC) curve and stepwise backward multivariable logistic regression analyses of
miR-125b expression were used to predict the disease outcome at three and six months after initiation of
treatment.
Results: The expression of miR-125b in the PBMCs and plasma of treatment-naïve early RA patients was
significantly lower than that of HC and increased significantly after three months of treatment, particularly in
responders. However, only the cellular expression of miR-125b was inversely correlated with disease activity.
MiR-125b expression in PBMCs was higher in responders than in non-responders after three months (p = 0.042).
Using ROC analysis, the cellular expression of miR-125b, but not the disease activity at baseline, predicted the
treatment response after three months of therapy (area under the curve 0.652 (95 % CI 0.510 to 0.793); p = 0.048).
Conclusion: The expression of miR-125b in PBMCs of treatment-naïve patients may present a novel biomarker for
monitoring the treatment outcome during the early phase of RA.
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Background
Rheumatoid arthritis (RA), which affects approximately
1 % of the world population, is an autoimmune disease
that if not treated effectively is associated with persistent
synovitis, leading to severe joint destruction, develop-
ment of joint deformities, and increased risk of cardio-
vascular diseases [1]. A targeted therapy approach is an
optimal treatment strategy providing the best results for
suppressing inflammation, thus avoiding irreversible
joint damage and the development of comorbidities in
patients with RA [2]. Some patients achieve remission or
at least low disease activity shortly after the initiation of
treatment with conventional synthetic disease-modifying
antirheumatic drugs (cs-DMARDs), whereas others do
not respond despite combination therapy or the use of
biologic DMARDs. Despite tremendous progress in the
treatment of RA, long-term remission in many patients
and complete cure remain elusive [3, 4].
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One of the factors contributing to a lack of therapeutic
response may be the epigenetic regulation of gene ex-
pression that seems to escape current targeted therapies
[5]. Epigenetic modification is characterized by changes
in gene expression without alteration of the nucleotide
sequence. This process results from the posttranslational
modification of DNA-binding molecules and from the
posttranscriptional repression of targeted protein-coding
genes [6]. The latter mechanism is mediated by a large
number of small non-coding RNAs, including micro-
RNA (miRNAs). MicroRNAs can degrade/destabilize
targeted mRNA (gene interference) or inhibit protein
synthesis and thereby regulate crucial pathways and cellular
processes such as cell growth, differentiation, proliferation,
and cell death [7, 8]. Deregulation of some miRNAs has
been found in many diseases [9, 10], including autoimmune
inflammatory disorders such as RA [11–13]. There is evi-
dence that miRNAs can be secreted extracellularly and can
be present in plasma or serum in a stable form that is pro-
tected from endogenous RNase activity [14]. Furthermore,
several circulating miRNAs have already been suggested as
potential biomarkers of disease activity in RA [15, 16].
The identification of sensitive biomarkers that predict
the response to therapy during the early phases of RA
remains challenging. Recently, the circulating miR-125b
levels have been associated with chemotherapeutic re-
sistance in breast cancer patients [17], and an elevated
serum level of miR-125b has been suggested to be a po-
tential predictive biomarker of the treatment response to
rituximab in patients with RA [18]. To date, no study
has investigated the expression of miR-125b in patients
with treatment-naïve early RA. Therefore, the aim of our
study was to determine whether the expression of cellu-
lar or circulating miR-125b may predict the outcome of
treatment in patients with early RA.
Methods
Patients
Fifty-eight patients with early RA who fulfilled the 2010
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classification cri-
teria for RA [19], with a duration of symptoms <6 months
were included in this study and were prospectively
followed in the Prague Early RA Clinic (PERAC) at the
Institute of Rheumatology, Prague, Czech Republic as
previously described [20]. The control group consisted of
54 age-matched and sex-matched healthy individuals.
Disease activity was assessed using the 28-joint count
disease activity score-erythrocyte sedimentation rate
(DAS28-ESR) at baseline and at 3 and 6 months after
the initiation of treatment. The patients were catego-
rized into non-responders if they had moderate to high
disease activity (DAS28 ≥ 3.2) and into responders if they
achieved low disease activity or remission after 3 or
6 months of treatment.
RNA isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
by standard Ficoll (Greiner Bio-one, Leipzig, Germany)
density gradient centrifugation, and pellets were snap fro-
zen and stored at –80 °C until analysis. Plasma samples
were stored at –20 °C. Total cellular RNA was isolated by
miRNeasy Mini Kit (Qiagen, Hilden, Germany) according
to protocol. Residual DNA contamination was removed
using the RNase-Free DNase Set (Qiagen) as recom-
mended by the manufacturer. Circulating miRNAs were
isolated from plasma samples using phenol-chloroform
extraction as previously described [16]. Plasma samples
were spiked with 25 fmol each of 3 synthetic miRNAs
of Caenorhabditis elegans origin (cel-miR-39, cel-miR-54,
cel-miR-238) (Qiagen) after denaturation with Trizol LS
(Thermo Scientific, Waltham, MA, USA) [16]. The con-
centration of total RNA was measured using NanoDrop
2000 spectrophotometer (Thermo Scientific).
Reverse transcription and quantification of miRNAs
The expression of miR-125b in PBMCs and plasma sam-
ples of all patients with early RA at baseline and at
3 months of therapy was analyzed and compared to the
expression in PBMCs and plasma of HC. Overall, 5 ng
of total RNA was reverse-transcribed using TaqMan
microRNA Assays (Life Technologies) and TaqMan
MicroRNA Reverse Transcription Kit (Life Technologies)
in a Thermocycler MyCycler (Biorad, Hercules, CA, USA).
Next, TaqMan microRNA Assays (Life Technologies) and
TaqMan Universal PCR Master Mix, no AmpErase UNG
(Life Technologies) were used to quantify miRNA expres-
sion by quantitative polymerase chain reaction (qPCR) in
a 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA). Small nucleolar RNA
RNU44 for cellular miRNAs or the average of cel-miR-39,
cel-miR-54 and cel-miR-238 for circulating miRNAs (Life
Technologies) were used to normalize data in PBMCs or
plasma samples, respectively. X-fold calculation using the
delta cycle threshold (dCt) method was used for calculat-
ing the relative expression of miR-125b as follows:
2−
ðCt miR−125bCt RNU44=average of cel−miR−39; cel−miR−54;
and cel−miR−238Þ
Statistical analysis
The Mann-Whitney U test and Wilcoxon matched-pairs
signed rank test were used where appropriate. Spearman’s
correlation test and the Fisher transformation were
applied for analysis of correlation and partial correlation.
Receiver operating characteristic (ROC) curve analysis of
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miR-125b expression was performed to predict disease
outcome, and the area under the curve (AUC) with 95 %
confidence interval (CI) was calculated. To confirm the
ROC analysis, stepwise backward multivariable logistic re-
gression was performed. Data were presented as the mean
(SD) or median (range). P values <0.05 were considered
statistically significant. GraphPad Prism, version 6 soft-
ware was used for the statistical analyses.
Results
Clinical characteristics
The clinical characteristics of the patients are shown in
Table 1. Prior to treatment, 37patients had high disease
activity (DAS28 > 5.1), 15 patients had moderate disease
activity (DAS28 3.2–5.1), and 6 patients had low disease
activity (DAS28 < 3.2). Treatment with cs-DMARDs was
initiated in 56 patients at baseline: 49 patients were
treated with methotrexate (mean weekly dose of 15 mg
at 3 months), 1 patient was treated with leflunomide, 4
patients were treated with sulfasalazine (mean daily dose
of 2 g at 3 months), 2 patients were treated with anti-
malarial drugs (mean hydroxychloroquine dose 200 mg),
1 patient received a combination of methotrexate and
sulfasalazine, and 46 patients received glucocorticoids
(mean daily dose of 5 mg of prednisone or equivalent at
3 months). Two patients were receiving only glucocorti-
coids at 3 months either due to liver toxicity (methotrex-
ate was temporarily discontinued) or planned pregnancy
(cs-DMARD was not initiated within the 3 months).
After 3 months of treatment, there was significant reduc-
tion in disease activity served (DAS28 decreased from 5.6 ±
1.6 to 3.1 ± 1.4 and C-reactive protein (CRP) decreased
from 9.2 (0.3–152.2) to 3.1 (0.2–23.9) mg/l; p < 0.001 for all
comparisons). After 3 months of treatment, 24 patients
were in remission, 12 patients had low disease activity, 18
patients had moderate disease activity, and 4 patients had
high disease activity. The improvement continued: after
6 months of treatment, 28 patients were in remission, 15
patients had low disease activity, 12 patients had moderate
disease activity, and 3 patients had high disease activity.
The expression of miR-125b is lower in patients with
early RA
First, we determined miR-125b expression in patients
with early RA and in HC and the effect of treatment on
the expression of miR-125b. The baseline expression of
miR-125b in peripheral blood mononuclear cells (PBMCs)
(p = 0.001) and in plasma (p < 0.0001) was significantly
lower in patients with early RA than in HC and increased
significantly after 3 months of therapy (p = 0.006 and p =
0.001, respectively) (Fig. 1a, b). There was a significant
increase in miR-125b expression in responders only, com-
pared to patients who did not achieve remission or low
disease activity (Fig. 1c, d). Similar changes in the miR-
125b expression profile were observed after 3 months in
responders and non-responders after 6 months of treat-
ment (p = 0.006 and p = 0.001, respectively). Increase in
miR-125b expression over time was not associated with
the dose of glucocorticoids or methotrexate. Furthermore,
Table 1 Characteristics of patients with early rheumatoid arthritis (RA) and healthy controls (HC)
Early RA HC
Number 58 54
Sex, female/male, n 42/16 41/13
Age, years 54.93 ± 16.18 50.87 ± 15.11
Disease duration <6 months






Clinical characteristic Baseline 3 months 6 months
RF IgM positivity, % 52 NA NA NA
Anti-CCP positivity, % 66 NA NA NA
DAS28 5.56 ± 1.56 3.05 ± 1.42 2.86 ± 1.25 NA
CRP, mg/l 9.16 (0.30, 152.20) 3.10 (0.21, 23.85) 2.83 (0.24, 44.44) 1.02 (0.22, 4.36)
ESR, mm/h 27.00 (4.00, 107.00) 15.50 (2.00, 54.00) 14.00 (2.00, 74.00) NA
Data are expressed as the mean ± SD or median (range) according to the distribution. Anti-CCP anti-citrullinated antibodies, CRP C-reactive protein, DAS28 disease
activity score, ESR erythrocyte sedimentation rate, HC healthy controls, NA not analyzed, RF rheumatoid factor
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miR-125b expression in PBMCs also increased in the few
responders who were naïve to glucocorticoids (data not
shown). However, there was no association between cellu-
lar and circulating miR-125b (r = –0.222, p = 0.094) and
no association between the change in cellular or circulat-
ing miR-125b and an improvement in disease activity
(data not shown).
Cellular miR-125b is inversely correlated with disease activity
Next, we analyzed whether the expression of miR-125b
is associated with disease activity in patients with early
RA. We found that the baseline expression of cellular
miR-125b was inversely correlated with the DAS28 at
baseline (r = –0.407; p = 0.001) (Fig. 2), with baseline ESR
(r = –0.375; p = 0.003) and with CRP levels (r = –0.270;
p = 0.035). Using age-adjusted analysis, the inverse
correlation between miR-125b and disease activity
remained significant for DAS28 (r = –0.276; p = 0.032)
and ESR (r = –0.268; p = 0.042) but not for CRP levels
(r = –0.194; p = 0.137). No such correlations were demon-
strated for circulating miR-125b (r = 0.117, p = 0.384).
These data show that lower intracellular expression of
Fig. 1 The expression of miR-125b is reduced in peripheral blood mononuclear cells (a) and plasma samples (b) from patients with early rheumatoid
arthritis (ERA) compared with healthy controls (HC), and significantly increases after 3 months of therapy (M3), particularly in patients achieving
remission or low disease activity (responders), compared to non-responders (c, d). Horizontal line represents the median. P values were estimated using
the nonparametric unpaired Mann-Whitney U test to calculate differences in the expression of miR-125b between HC and patients with early RA, and
the nonparametric paired Wilcoxon test to calculate differences in the expression of miR-125b between patients with early RA before and after therapy
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miR-125b in PBMCs is present in treatment-naïve patients
with early RA, who have higher disease activity.
Baseline expression of cellular miR-125b predicts treatment
response
We also hypothesized that baseline expression of miR-
125b may predict treatment response. We demonstrated
that baseline cellular (but not circulating) expression of
miR-125b was higher in responders to treatment at
3 months than in non-responders (p = 0.042) (Fig. 3).
However, baseline miR-125b expression did not differ
between responders and non-responders to treatment at
the 6-month follow up (p = 0.321), probably due to the
small number of non-responders (n = 15).
Based on the data showing that baseline miR-125b ex-
pression is higher in responders than in non-responders
at 3 months, we performed ROC curve analysis to deter-
mine the predictive value of baseline miR-125b expression
and conventional baseline parameters of disease activity,
including DAS28, CRP levels and ESR, in separating pa-
tients with early RA who achieve an optimal treatment
outcome (remission or low disease activity) from those
who do not have such a response. This analysis showed
that baseline miR-125b expression in PBMCs was the only
predictor of achieving an optimal treatment outcome after
3 months (Fig. 4). The AUC for baseline miR-125b expres-
sion was 0.663 (95 % CI 0.520 to 0.805; p = 0.048). We
then performed stepwise backward multivariate logistic
regression analysis of baseline cellular miR-125b expres-
sion in combination with DAS28 at 3 months. This ana-
lysis confirmed the ROC analysis outcomes and showed
that baseline miR-125b expression was a significant and
independent predictor of treatment response at 3 months
(OR 3.717 95 % CI 1.005 to 13.745; p = 0.049).
Discussion
In the present study, we report that (1) baseline miR-
125b expression is lower in patients with early RA than
in healthy subjects, (2) cellular miR-125b expression is
inversely correlated with RA disease activity, (3) miR-
125b expression increased after 3 months of conven-
tional therapy, and (4) higher baseline cellular miR-125b
expression predicts the early optimal therapeutic response
(DAS28 < 3.2).
The expression of several miRNAs is altered in pa-
tients with RA compared to the healthy population [21].
Consistent with previous studies demonstrating reduced
expression of miR-125b in some autoimmune diseases,
particularly in psoriatic keratinocytes and systemic lupus
erythematosus (SLE) CD4+ T lymphocytes [22, 23], we
Fig. 2 Inverse correlation between the initial expression of miR-125b in peripheral blood mononuclear cells and baseline disease activity assessed
by the 28-joint count disease activity score (DAS28). Nonparametric Spearman correlation analysis was used to test the association between baseline
miR-125b and disease activity
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found that the expression of miR-125b in both PBMCs
and plasma is lower in treatment-naïve patients with
early RA than in HC.
MiR-125b has been described as a negative regulator
of TNFα and other pro-inflammatory cytokines such as
interferon (IFN)γ, chemokine CCL4 and matrix metallo-
proteinase (MMP)-13 [24–27]. Thus, we hypothesize that
reduced expression of miR-125b could be associated with
increased inflammation in RA. However, Duroux-Richard
et al. [18] reported increased expression of miR-125b in
whole blood and serum from patients with established
RA. The discrepancy between this report [18] and our
data may be explained by the different material used for
miRNA analysis and particularly by the different stages of
the disease. It was previously shown that the expression
profile of miRNAs is different in whole blood and PBMCs
[28]. Moreover, although our study included treatment-
naïve patients with RA of short disease duration, Duroux-
Richard et al. [18] studied patients with established and
long-lasting RA, consistent with our recent study that
showed differential expression of circulating miRNAs in
early and in established RA [16].
We observed inverse correlation between baseline
expression of cellular miR-125b and the parameters of
disease activity in patients with early RA. This result is
consistent with an inhibitory effect of miR-125b on the
expression of pro-inflammatory cytokines, cell prolif-
eration, and apoptosis [24–27, 29]. miR-125b has been in-
versely associated with age, as its expression is higher in the
immune cells of young donors than in older donors [29].
Considering age as a potential confounder, age-adjustment
confirmed our data, and the association between baseline
miR-125b expression in PBMCs and clinical disease activity
remained significant. Furthermore, we demonstrated
upregulation of miR-125b in PBMCs from patients
with early RA after 3 months of therapy, which was
particularly pronounced in responders. This finding
may be due to stronger inhibition of pro-inflammatory
cytokines, which would lead to a better clinical outcome
over time. This hypothesis is supported by a recent obser-
vation of increased levels of circulating miR-125b in RA
responders to anti-TNFα/DMARD combination therapy
[30], though the source of miRNA was not cellular.
Although one study demonstrated upregulation of
miR-125b in human B lymphoblast cells after exposure
to dexamethasone [31], this upregulation was transient.
In our study, we found no association between the dose
of glucocorticoids and change in miR-125b expression
over time. Furthermore, miR-125b expression in PBMCs
also increased in the few responders who were naïve to
Fig. 3 Baseline expression of miR-125b in peripheral blood mononuclear cells is higher in responders than in non-responders. Patients with early
rheumatoid arthritis were categorized as non-responders if they had moderate to high disease activity assessed by the 28-joint count disease activity
score (DAS28 ≥ 3.2) and as responders if they achieved low disease activity or remission (DAS28 < 3.2) after 3 months of treatment. Horizontal
line represents the median. P values were estimated using the nonparametric unpaired Mann-Whitney U test to calculate differences in the
expression of miR-125b between responders and non-responders
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glucocorticoids. We also did not observe association be-
tween the dose of methotrexate and change in miR-125b
over time, therefore, it can be speculated that the change
in miR-125b expression may not be influenced by the
type of therapy, but rather by improvement in disease
activity.
To determine the treatment outcome, we performed a
predictive analysis by plotting an ROC curve and by
logistic regression analysis of the baseline expression
of miR-125b and disease activity over time. We demon-
strated that higher baseline expression of miR-125b pre-
dicts remission or low disease activity after 3 months of
therapy. Crucial pro-inflammatory cytokines such as TNFα
or IL-6 [24–27, 32] are known downstream targets of miR-
125. Therefore, we suggest that the higher cellular miR-
125b expression contributes to the achievement of lower
inflammatory status and thus, could serve as a biomarker
for the early treatment response in patients with early RA.
However, no such finding was observed for circulating
miR-125b or for miR-125b in PBMCs at the 6-month fol-
low up. We found no correlation between circulating and
miR-125b containing PBMCs; therefore, other compart-
ments or mechanisms may influence the levels of circulat-
ing miRNAs. Because miR-125b has been demonstrated to
be a biomarker of resistance to chemotherapy in pancreatic
cancer [32] and circulating miR-125b has been demon-
strated to be a predictive biomarker of response to biologic
treatment in established RA [18, 30], further studies evalu-
ating the role of miR-125b in RA are needed.
Conclusion
In conclusion, we have demonstrated that the expression
of miR-125b in PBMCs is lower in treatment-naïve pa-
tients with early RA and mainly in patients who do not
reach the optimal therapeutic outcome at 3-month
follow-up. The expression of cellular, but not circulating,
miR-125b is inversely associated with RA disease activity
and may serve as a potential biomarker of treatment
response in early RA.
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